Articles
22.11.2021
NICE cost effective medicines

When making a decision about the approval of a new product NICE (National Institute for Health and C...

Read more
Articles
17.11.2021
Head of agencies HAG

The Head of Agency Group (HAG) is a recently launched network created by the European Health Technol...

Read more
Articles
08.11.2021
High cost oncology combination therapy

The use of combination therapy is increasingly becoming the standard of care in oncology as cancers ...

Read more
Articles
03.11.2021
International Horizon Scanning Initiative

The IHSI is an independent legal entity, with representatives from eight member countries.

Read more
Articles
25.10.2021
Hazard ratio and HTA agencies

In oncology, a hazard ratio (HR) is commonly used to estimate the treatment effect for survival endp...

Read more
Articles
20.10.2021
The QALY shortfall

The QALY Shortfall aims to capture and recognise disease severity by assessing the degree of quality...

Read more
Articles
11.10.2021
The product life cycle

An overview of the product life cycle. The product life cycle must be managed efficiently to generat...

Read more
Articles
06.10.2021
PMA Perspective Q3 2021

Insights from pharmaceuticals, market access and Team Remap Q3 2021.

Read more
Articles
04.10.2021
Good value propositions

We outline the 3 key components of a good value proposition, designed to demonstrate the value of ne...

Read more
Articles
27.09.2021
Access for rare disease treatments

Innovative therapies for rare diseases may only be available in a select number of countries in Euro...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.